Keudell Morrison Wealth Management Takes $119,000 Position in Haleon plc (NYSE:HLN)

Keudell Morrison Wealth Management purchased a new stake in shares of Haleon plc (NYSE:HLN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,001 shares of the company’s stock, valued at approximately $119,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Pinnacle Bancorp Inc. boosted its holdings in Haleon by 29.8% in the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after purchasing an additional 1,421 shares in the last quarter. Blue Barn Wealth LLC lifted its position in Haleon by 7.3% during the 4th quarter. Blue Barn Wealth LLC now owns 20,858 shares of the company’s stock worth $172,000 after acquiring an additional 1,425 shares during the last quarter. Defined Wealth Management LLC lifted its position in Haleon by 5.8% during the 1st quarter. Defined Wealth Management LLC now owns 29,009 shares of the company’s stock worth $246,000 after acquiring an additional 1,590 shares during the last quarter. Essex Financial Services Inc. raised its position in shares of Haleon by 13.7% during the first quarter. Essex Financial Services Inc. now owns 14,288 shares of the company’s stock valued at $121,000 after buying an additional 1,727 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC raised its position in shares of Haleon by 6.1% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 32,989 shares of the company’s stock valued at $271,000 after buying an additional 1,905 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Performance

Haleon stock traded down $0.06 during midday trading on Monday, hitting $8.84. The company’s stock had a trading volume of 2,000,452 shares, compared to its average volume of 5,248,954. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73. The company has a 50-day moving average price of $8.45 and a two-hundred day moving average price of $8.37. The company has a market cap of $40.36 billion, a price-to-earnings ratio of 29.67, a PEG ratio of 2.55 and a beta of 0.25.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The company had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. As a group, sell-side analysts predict that Haleon plc will post 0.46 earnings per share for the current year.

Analyst Ratings Changes

HLN has been the topic of a number of analyst reports. Argus reissued a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. Berenberg Bank initiated coverage on shares of Haleon in a report on Wednesday, June 5th. They issued a “buy” rating on the stock. Finally, HSBC initiated coverage on shares of Haleon in a report on Wednesday, April 17th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.